Finoriq research workspace
PRECIGEN, INC. (PGEN) SEC Filings & Filing Highlights
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell. Review PGEN SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1/1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis. Further, it provides UltraPorator, a proprietary electroporation device. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.
- Company
- PRECIGEN, INC. (PGEN)
- Ticker
- PGEN
- Market Cap
- $1.8B
- Latest Price
- $5.03
- Industry
- Biotech & Pharma
PRECIGEN, INC. (PGEN) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for PRECIGEN, INC. (PGEN).
| Event | Form | Date |
|---|---|---|
| At the 2026 Annual Meeting, the Company’s stockholders elected each of the persons listed below...At the 2026 Annual Meeting, the Company’s stockholders (i) elected each of the persons listed below as a director for a one-year term, (ii)... | 8-K5.07 | 2026-06-24 |
| At the Annual Meeting of Stockholders of Precigen, Inc. (the “Company”) held on June 18, 2026 (...At the Annual Meeting of Stockholders of Precigen, Inc. (the “Company”) held on June 18, 2026 (the “2026 Annual Meeting”), the Company’s st... | 8-K5.02 | 2026-06-24 |
| Precigen Reports First Quarter 2026 Financial Results and Business UpdatesPrecigen Reports First Quarter 2026 Financial Results and Business Updates | 8-K2.02 | 2026-05-13 |
| Precigen Reports Full Year 2025 Financial Results and Business UpdatesPrecigen Reports Full Year 2025 Financial Results and Business Updates | 8-K2.02 | 2026-03-25 |
| Precigen Reports Third Quarter 2025 Financial Results and Business UpdatesPrecigen Reports Third Quarter 2025 Financial Results and Business Updates | 8-K2.02 | 2025-11-13 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.